GSK logo

GSK
Glaxosmithkline plc - ADR

9,506
Mkt Cap
$99.08B
Volume
4.03M
52W High
$51.46
52W Low
$32.38
PE Ratio
13.82
GSK Fundamentals
Price
$48.45
Prev Close
$49.12
Open
$48.90
50D MA
$48.44
Beta
0.26
Avg. Volume
3.12M
EPS (Annual)
$1.61
P/B
4.55
Rev/Employee
$584,193.84
Loading...
Loading...
News
all
press releases
Deutsche Bank Aktiengesellschaft Boosts GSK (LON:GSK) Price Target to GBX 1,675
Deutsche Bank Aktiengesellschaft raised their price objective on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a "hold" rating in a research note on Thursday...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
GSK (LON:GSK) Shares Pass Above 200-Day Moving Average - Here's Why
GSK (LON:GSK) Share Price Passes Above 200-Day Moving Average - Should You Sell...
MarketBeat·11h ago
News Placeholder
GSK (NYSE:GSK) Stock Crosses Above 200-Day Moving Average - Here's Why
GSK (NYSE:GSK) Stock Crosses Above 200-Day Moving Average - Time to Sell...
MarketBeat·11h ago
News Placeholder
Here's Why GSK (GSK) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·1d ago
News Placeholder
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?
MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.
Zacks·1d ago
News Placeholder
Why GSK (GSK) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·4d ago
News Placeholder
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSKs B7-H3 Antibody Drug Conjugate (ADC)
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (GSK, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1...
Business Wire·4d ago
News Placeholder
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.read more...
Benzinga·4d ago
News Placeholder
AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties
AnaptysBio asks a Delaware court to dismiss Tesaro's breach claim, citing anti-SLAPP law in a dispute over Jemperli royalties and licensing rights.read more...
Benzinga·7d ago
News Placeholder
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs
The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.
Stocktwits·8d ago
<
1
2
...
>

Latest GSK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.